SCHEMBL3284891

SCHEMBL3284891

N#Cc1cnccc1C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.50
SIRT3 Q9NTG7 2/20 0.50
CDC7 O00311 2/20 0.45
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
KDM6B O15054 1/20 0.43
KDM4A O75164 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
KMT2A Q03164 1/20 0.43
KDM4D Q6B0I6 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HTT P42858 2/20 0.41
F7 P08709 1/20 0.40
F3 P13726 1/20 0.40
SARM1 Q6SZW1 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
SIRT6 Q8N6T7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30874483 0.85 SIRT3 (0.55) TDP1SIRT3CDC7KDM4EALDH1A1
SCHEMBL2848389 0.83 KDM4C (0.53) TDP1KDM4EALDH1A1MEN1KDM6B
SCHEMBL29952392 0.83 KDM4C (0.53) TDP1KDM4EALDH1A1MEN1KDM6B
SCHEMBL5610674 0.83 TDP1 (0.52) TDP1SIRT3CDC7KDM4EALDH1A1
SCHEMBL10639037 0.81 HIPK2 (0.40) TDP1SIRT3KDM4EALDH1A1MEN1
SCHEMBL13320901 0.81 MAPT (0.44) TDP1SIRT3KDM4EALDH1A1MEN1
SCHEMBL4656245 0.79 HTT (0.38) TDP1SIRT3CDC7KDM4EALDH1A1
SCHEMBL4656246 0.79 HTT (0.38) TDP1SIRT3CDC7KDM4EALDH1A1
SCHEMBL2847922 0.77 ALDH1A1 (0.58) TDP1KDM4EALDH1A1KMT2AKDM4C
SCHEMBL29467363 0.77 ALDH1A1 (0.58) TDP1KDM4EALDH1A1KMT2AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 US disclosed
US-11999730-B1 AKT1 modulators ALTEROME THERAPEUTICS, INC. (US) 2024-06-04 US disclosed
US-20240174667-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-05-30 US disclosed
US-7709503-B2 Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2010-05-04 US disclosed
US-20060223801-A1 Pyrrol derivatives with antibacterial activity ASTRAZENECA AB (SE) 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 TDP1 1721/4885SIRT3 2481/4885CDC7 129/4885
US-20060223801-A1 Pyrrol derivatives with antibacterial activity PEF1, PEPD, PELP1 TDP1 1516/4885SIRT3 2681/4885CDC7 3177/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 TDP1 1721/4885SIRT3 2481/4885CDC7 129/4885
US-11999730-B1 AKT1 modulators AKT1S1, AKT1, AKT2 TDP1 1721/4885SIRT3 2481/4885CDC7 129/4885
US-20240174667-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 TDP1 1721/4885SIRT3 2481/4885CDC7 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.